£3.4M
iLoF secures 3.38m in seed funding led by Faber to accelerate personalized drug discovery platforms.
The seed round was led by Faber with participation from international venture funds to support clinical trial operations.
"For hundreds of years, treatments have been developed with the assumption they will work for everyone. However, each person is different, and for many severe diseases such as Alzheimer’s, multiple factors can contribute to the effectiveness of a treatment on a given patient."
